Diabetes Clinical Trial
— CAMOfficial title:
The Establishment of "Empowerment-based Complementary and Alternative Medicine (ECAM) " Educational Program to Improve Complementary and Alternative Medicine(CAM) Health Literacy in Patients With Diabetes: Dilemma Analysis, Integration Into Practice and Outcome Evaluation
This phase study will use a randomized trial method to evaluate the performance of the ECAM educational app in the promotion of CAM health literacy and communication among patients with diabetes.
Status | Not yet recruiting |
Enrollment | 86 |
Est. completion date | July 31, 2025 |
Est. primary completion date | March 4, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 20 Years to 90 Years |
Eligibility | Inclusion Criteria: - People over the age of 20 - diagnosis of diabetes at least 12 months before the interview; and - The use of CAM at least 3 months - Sufficient mental ability to understand the informed consent form and sign it. Exclusion Criteria: - Participants will be excluded by an assistant researcher if they serious physical condition and hard of hearing and seeing. |
Country | Name | City | State |
---|---|---|---|
Taiwan | CHENG GUNG MEMORIAL HOSPITAL, Linkou | Taoyuan City | Guishan District |
Lead Sponsor | Collaborator |
---|---|
Chang Gung University of Science and Technology | Chang Gung Memorial Hospital, National Science and Technology Council |
Taiwan,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Understanding the benefits-risks of complementary therapies (CTs) use scale Alternative Medicine (CAM) use questionnaire | Measure patients' understanding of benefit-risk management on CAM use, the minimum and maximum values,and higher scores .The minimum is 16,maximum values is 64,The lower the score, the poorer the understanding. | Pre-test (baseline), 2, 3 months after intervention | |
Primary | Quality of life questionnaire | Measure patients' understanding of benefit-risk management on CAM use, the minimum and maximum values,and higher scores .The minimum is 7,maximum values is 105,The lower the score, the poorer the understanding. | Pre-test (baseline), 2, 3 months after intervention | |
Primary | Diabetes Empowerment scale | Measure patients' understanding of benefit-risk management on CAM use, the minimum and maximum values,and higher scores .The minimum is 10,maximum values is 40,The lower the score, the poorer the understanding. | Pre-test (baseline), 2, 3 months after intervention | |
Secondary | Blood Glucose (GLU) | Normal blood glucose levels typically range between 70 and 100 milligrams per deciliter (mg/dL) when fasting (not having eaten for at least 8 hours). | Pre-test (baseline),3 months after intervention | |
Secondary | Glycated Hemoglobin(HbA1c) | Glycated Hemoglobin, or hemoglobin A1c, is a measure of average blood glucose levels over the past two to three months. An average HbA1c level is below 5.7%, while levels between 5.7% and 6.4% may indicate prediabetes, and levels of 6.5% or higher usually indicate diabetes. | Pre-test (baseline),3 months after intervention | |
Secondary | ALanine aminoTransferase,Glutamic Pyruvic Transaminase(ALT/GPT) | Normal ranges for alanine aminotransferase and glutamic pyruvic transaminase levels can vary depending on the laboratory and the individual's age, sex, and health status. Typically, normal ALT/GPT levels are below 40 international units per liter (IU/L) for men and below 35 IU/L for women. Persistent elevation of ALT/GPT levels may warrant further investigation to determine the underlying cause and appropriate management. | Pre-test (baseline),3 months after intervention | |
Secondary | ASpartate aminoTransferase,Glutamic Oxaloacetic Transaminase (AST/GOT) | normal aspartate aminotransferase,glutamic oxaloacetic transaminase levels are below 40 international units per liter (IU/L) for men and women. Persistent elevation of AST/GOT levels may indicate underlying health issues and may require further evaluation to determine the cause and appropriate management. | Pre-test (baseline),3 months after intervention | |
Secondary | Blood Urea Nitrogen(BUN) | Normal blood urea nitrogen levels generally fall within the range of 7 to 20 milligrams per deciliter (mg/dL) in adults. Still, this range can vary depending on factors such as age, sex, and underlying health conditions. Interpretation of BUN levels should be done in conjunction with other clinical findings and additional tests to determine the underlying cause and guide appropriate treatment. | Pre-test (baseline),3 months after intervention | |
Secondary | Creatinine(CREA) | Normal creatinine levels can vary depending on factors such as age, sex, muscle mass, and ethnicity. Generally, normal creatinine levels fall within the following ranges: For adult men: 0.6 to 1.2 milligrams per deciliter (mg/dL) For adult women: 0.5 to 1.1 mg/dL |
Pre-test (baseline),3 months after intervention | |
Secondary | High Density Lipoprotein(HDL) | Normal high-density lipoprotein cholesterol levels are generally considered to be: Above 60 milligrams per deciliter (mg/dL) is considered high and is associated with a lower risk of heart disease. Below 40 mg/dL for men and below 50 mg/dL for women is considered low and may increase the risk of heart disease. |
Pre-test (baseline),3 months after intervention | |
Secondary | Total Bilirubin(T.BIL) | Normal total bilirubin levels typically range from 0.3 to 1.2 milligrams per deciliter (mg/dL) in adults. | Pre-test (baseline),3 months after intervention | |
Secondary | Serum total cholesterol(TC) | Average total cholesterol levels vary depending on factors such as age, sex, and individual health status. Generally, total cholesterol levels below 200 milligrams per deciliter (mg/dL) are considered desirable. In contrast, levels between 200 and 239 mg/dL are borderline high, and levels above 240 mg/dL are considered high and may increase the risk of heart disease. | Pre-test (baseline),3 months after intervention | |
Secondary | Triglyceride (TG) | Normal triglyceride levels typically fall below 150 milligrams per deciliter (mg/dL) in adults. Triglyceride levels between 150 and 199 mg/dL are considered borderline high, levels between 200 and 499 mg/dL are considered high, and levels of 500 mg/dL or above are considered very high. | Pre-test (baseline),3 months after intervention | |
Secondary | Glomerular filtration rate(GFR) | Normal glomerular filtration rate levels vary depending on factors such as age, sex, and body size. In adults, a GFR above 90 mL/min/1.73 m² is generally considered normal, while values below this range may indicate decreased kidney function. GFR values below 60 mL/min/1.73 m² for three months or longer are indicative of chronic kidney disease (CKD). | Pre-test (baseline),3 months after intervention | |
Secondary | Albumin to Creatinine Ratio (ACR) | Normal albumin to creatinine ratio levels are typically less than 30 mg/g. ACR levels between 30 and 300 mg/g are considered moderately elevated, and levels above 300 mg/g are considered severely elevated. | Pre-test (baseline),3 months after intervention |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05594446 -
Morphometric Study of the Legs and Feet of Diabetic Patients in Order to Collect Data Intended to be Used to Measure by Dynamometry the Pressures Exerted by Several Medical Compression Socks at the Level of the Forefoot
|
||
Completed |
NCT03975309 -
DHS MIND Metabolomics
|
||
Completed |
NCT01855399 -
Technologically Enhanced Coaching: A Program to Improve Diabetes Outcomes
|
N/A | |
Completed |
NCT01819129 -
Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination With Insulin Glargine and Metformin in Adults With Type 2 Diabetes
|
Phase 3 | |
Recruiting |
NCT04984226 -
Sodium Bicarbonate and Mitochondrial Energetics in Persons With CKD
|
Phase 2 | |
Recruiting |
NCT05007990 -
Caregiving Networks Across Disease Context and the Life Course
|
||
Active, not recruiting |
NCT04420936 -
Pragmatic Research in Healthcare Settings to Improve Diabetes and Obesity Prevention and Care for Our Program
|
N/A | |
Recruiting |
NCT03549559 -
Imaging Histone Deacetylase in the Heart
|
N/A | |
Completed |
NCT04903496 -
Clinical Characteristics and Disease Burden of Diabetic Patients Based on Tianjin Regional Database
|
||
Completed |
NCT01437592 -
Investigating the Pharmacokinetic Properties of NN1250 in Healthy Chinese Subjects
|
Phase 1 | |
Completed |
NCT01696266 -
An International Survey on Hypoglycaemia Among Insulin-treated Patients With Diabetes
|
||
Completed |
NCT04082585 -
Total Health Improvement Program Research Project
|
||
Completed |
NCT03390179 -
Hyperglycemic Response and Steroid Administration After Surgery (DexGlySurgery)
|
||
Not yet recruiting |
NCT05029804 -
Effect of Walking Exercise Training on Adherence to Disease Management and Metabolic Control in Diabetes
|
N/A | |
Recruiting |
NCT05294822 -
Autologous Regenerative Islet Transplantation for Insulin-dependent Diabetes
|
N/A | |
Completed |
NCT04427982 -
Dance and Diabetes/Prediabetes Self-Management
|
N/A | |
Completed |
NCT02356848 -
STEP UP to Avert Amputation in Diabetes
|
N/A | |
Completed |
NCT03292185 -
A Trial to Investigate the Single Dose Pharmacokinetics of Insulin Degludec/Liraglutide Compared With Insulin Degludec and Liraglutide in Healthy Chinese Subjects
|
Phase 1 | |
Active, not recruiting |
NCT05477368 -
Examining the Feasibility of Prolonged Ketone Supplement Drink Consumption in Adults With Type 2 Diabetes
|
N/A | |
Completed |
NCT04496401 -
PK Study in Diabetic Transplant récipients : From Twice-daily Tacrolimus to Once-daily Extended-release Tacrolimus
|
Phase 4 |